MetaVia Inc.
MTVA
Classifica tra le azioni
#32866
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Prezzo delle azioni
$1.30
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$8.53M
Variazione (1 giorno)
-5.47%
Variazione (1 anno)
-20.55%
Paese
US
Scambia MetaVia Inc. (MTVA)
Categoria
Healthcare
Capitalizzazione di mercato di MetaVia Inc.(MTVA)
Capitalizzazione di mercato: $8.53M
A partire dal October 2026, MetaVia Inc. ha una capitalizzazione di mercato pari a $8.53M. Questo rende MetaVia Inc. la 32866th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di MetaVia Inc. dal 2016 al 2026
MTVA in paragone con la classifica dei più popolari stocks
| Il prezzo per MTVA | Attivo B | Capitalizzazione del mercato a B | Risultati | |
|---|---|---|---|---|
$505,878
$16.65M
|
$5.167T | +31,035,372.78% | ||
|
$490,971
$16.65M
|
$5.015T | +30,120,828.45% | ||
|
$402,232
$16.65M
|
$4.108T | +24,676,737.32% | ||
|
$382,015
$16.65M
|
$3.902T | +23,436,418.37% | ||
|
$263,311
$16.65M
|
$2.689T | +16,153,933.99% |
